FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386102775> ?p ?o ?g. }

• W4386102775 abstract "In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with divergent outcomes and treatment responses. In this study, we sought to derive molecular phenotypes in critically ill adults with sepsis, determine their overlap with previous ARDS phenotypes, and evaluate whether they respond differently to treatment in completed sepsis trials.We used clinical data and plasma biomarkers from two prospective sepsis cohorts, the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study (N=1140) and the Early Assessment of Renal and Lung Injury (EARLI) study (N=818), in latent class analysis (LCA) to identify the optimal number of classes in each cohort independently. We used validated models trained to classify ARDS phenotypes to evaluate concordance of sepsis and ARDS phenotypes. We applied these models retrospectively to the previously published Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis and Septic Shock (PROWESS-SHOCK) trial and Vasopressin and Septic Shock Trial (VASST) to assign phenotypes and evaluate heterogeneity of treatment effect.A two-class model best fit both VALID and EARLI (p<0·0001). In VALID, 804 (70·5%) of the 1140 patients were classified as hypoinflammatory and 336 (29·5%) as hyperinflammatory; in EARLI, 530 (64·8%) of 818 were hypoinflammatory and 288 (35·2%) hyperinflammatory. We observed higher plasma pro-inflammatory cytokines, more vasopressor use, more bacteraemia, lower protein C, and higher mortality in the hyperinflammatory than in the hypoinflammatory phenotype (p<0·0001 for all). Classifier models indicated strong concordance between sepsis phenotypes and previously identified ARDS phenotypes (area under the curve 0·87-0·96, depending on the model). Findings were similar excluding participants with both sepsis and ARDS. In PROWESS-SHOCK, 1142 (68·0%) of 1680 patients had the hypoinflammatory phenotype and 538 (32·0%) had the hyperinflammatory phenotype, and response to activated protein C differed by phenotype (p=0·0043). In VASST, phenotype proportions were similar to other cohorts; however, no treatment interaction with the type of vasopressor was observed (p=0·72).Molecular phenotypes previously identified in ARDS are also identifiable in multiple sepsis cohorts and respond differently to activated protein C. Molecular phenotypes could represent a treatable trait in critical illness beyond the patient's syndromic diagnosis.US National Institutes of Health." @default.
• W4386102775 created "2023-08-24" @default.
• W4386102775 creator A5001223291 @default.
• W4386102775 creator A5010687095 @default.
• W4386102775 creator A5011336207 @default.
• W4386102775 creator A5017038212 @default.
• W4386102775 creator A5017147813 @default.
• W4386102775 creator A5017253129 @default.
• W4386102775 creator A5018528325 @default.
• W4386102775 creator A5034626074 @default.
• W4386102775 creator A5040433822 @default.
• W4386102775 creator A5041459074 @default.
• W4386102775 creator A5045602818 @default.
• W4386102775 creator A5048677870 @default.
• W4386102775 creator A5051444860 @default.
• W4386102775 creator A5051494461 @default.
• W4386102775 creator A5052576862 @default.
• W4386102775 creator A5061493688 @default.
• W4386102775 creator A5062212651 @default.
• W4386102775 creator A5064621406 @default.
• W4386102775 creator A5064708000 @default.
• W4386102775 creator A5066441344 @default.
• W4386102775 creator A5072741865 @default.
• W4386102775 creator A5079439710 @default.
• W4386102775 creator A5081932765 @default.
• W4386102775 creator A5084111348 @default.
• W4386102775 creator A5084612869 @default.
• W4386102775 creator A5088547412 @default.
• W4386102775 creator A5090576091 @default.
• W4386102775 date "2023-08-01" @default.
• W4386102775 modified "2023-10-14" @default.
• W4386102775 title "Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials" @default.
• W4386102775 cites W1991209345 @default.
• W4386102775 cites W2021701428 @default.
• W4386102775 cites W2098558453 @default.
• W4386102775 cites W2104825124 @default.
• W4386102775 cites W2108153775 @default.
• W4386102775 cites W2124519382 @default.
• W4386102775 cites W2127482775 @default.
• W4386102775 cites W2146384083 @default.
• W4386102775 cites W2161328469 @default.
• W4386102775 cites W2274346642 @default.
• W4386102775 cites W2280404143 @default.
• W4386102775 cites W2515625652 @default.
• W4386102775 cites W2608341641 @default.
• W4386102775 cites W2618861551 @default.
• W4386102775 cites W2750720130 @default.
• W4386102775 cites W2789013418 @default.
• W4386102775 cites W2792583887 @default.
• W4386102775 cites W2806376027 @default.
• W4386102775 cites W2885500852 @default.
• W4386102775 cites W2894810674 @default.
• W4386102775 cites W2904268023 @default.
• W4386102775 cites W2944988359 @default.
• W4386102775 cites W2980621316 @default.
• W4386102775 cites W2998886261 @default.
• W4386102775 cites W3014051002 @default.
• W4386102775 cites W3016869725 @default.
• W4386102775 cites W3033281129 @default.
• W4386102775 cites W3036339803 @default.
• W4386102775 cites W3081015435 @default.
• W4386102775 cites W3102547229 @default.
• W4386102775 cites W3125603473 @default.
• W4386102775 cites W3178523294 @default.
• W4386102775 cites W3178796382 @default.
• W4386102775 cites W3201331497 @default.
• W4386102775 cites W3215954095 @default.
• W4386102775 cites W4200563264 @default.
• W4386102775 cites W4205876010 @default.
• W4386102775 cites W4243836839 @default.
• W4386102775 cites W4283022274 @default.
• W4386102775 cites W4321092858 @default.
• W4386102775 doi "https://doi.org/10.1016/s2213-2600(23)00237-0" @default.
• W4386102775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37633303" @default.
• W4386102775 hasPublicationYear "2023" @default.
• W4386102775 type Work @default.
• W4386102775 citedByCount "1" @default.
• W4386102775 countsByYear W43861027752023 @default.
• W4386102775 crossrefType "journal-article" @default.
• W4386102775 hasAuthorship W4386102775A5001223291 @default.
• W4386102775 hasAuthorship W4386102775A5010687095 @default.
• W4386102775 hasAuthorship W4386102775A5011336207 @default.
• W4386102775 hasAuthorship W4386102775A5017038212 @default.
• W4386102775 hasAuthorship W4386102775A5017147813 @default.
• W4386102775 hasAuthorship W4386102775A5017253129 @default.
• W4386102775 hasAuthorship W4386102775A5018528325 @default.
• W4386102775 hasAuthorship W4386102775A5034626074 @default.
• W4386102775 hasAuthorship W4386102775A5040433822 @default.
• W4386102775 hasAuthorship W4386102775A5041459074 @default.
• W4386102775 hasAuthorship W4386102775A5045602818 @default.
• W4386102775 hasAuthorship W4386102775A5048677870 @default.
• W4386102775 hasAuthorship W4386102775A5051444860 @default.
• W4386102775 hasAuthorship W4386102775A5051494461 @default.
• W4386102775 hasAuthorship W4386102775A5052576862 @default.
• W4386102775 hasAuthorship W4386102775A5061493688 @default.
• W4386102775 hasAuthorship W4386102775A5062212651 @default.
• W4386102775 hasAuthorship W4386102775A5064621406 @default.
• W4386102775 hasAuthorship W4386102775A5064708000 @default.
• W4386102775 hasAuthorship W4386102775A5066441344 @default.
• W4386102775 hasAuthorship W4386102775A5072741865 @default.

• next